New Rhein Healthcare Investors
Nishant Rastogi serves as the VP and Head of Transactions at New Rhein Healthcare Investors since July 2018, focusing on operationally-oriented life sciences investments through a private equity model. In addition to this role, Nishant is a member of the Board of Directors at Corsair Pharma, and an investor at Theranica, while also holding positions as a Board Observer at Alveus Therapeutics, Butterfly Medical, and Neuraptive Therapeutics. Prior experience includes Board Observer roles at American Injectables and FineHeart, as well as MBA Associate positions at Digitalis Ventures and Linden Capital Partners. Nishant's academic background includes a B.A. in Economics and Mathematical Finance from Dartmouth College, an accelerated MBA from Northwestern University's Kellogg School of Management, and additional studies in physiology and pharmacology at Harvard Medical School.
This person is not in any teams
This person is not in any offices
New Rhein Healthcare Investors
New Rhein is a Venture Capital/ Private Equity investor. Its partners are former pharmaceutical industry executives having both operational and M&A experience. New Rhein invests in healthcare companies with the objective of helping management teams build their business into a profile strategic investors would find attractive. We use our knowledge of what strategic buyers want and our relationships to help our portfolio companies achieve this goal. Investment areas of focus include specialty Rx (eg hospital), branded and difficult to make Gx, OTC, biologics, vaccines, and emerging markets (in particular China and Brazil). We are interested in product only deals, carve-outs and entire company purchases.